GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » EPS (Basic)

Athersys (Athersys) EPS (Basic) : $-2.03 (TTM As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Athersys EPS (Basic)?

Athersys's basic earnings per share (Basic EPS) for the three months ended in Sep. 2023 was $-0.15. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.03.

Athersys's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.03.

Athersys's EPS without NRI for the three months ended in Sep. 2023 was $-0.15. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -2.03.

During the past 3 years, the average EPS without NRI Growth Rate was -180.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -141.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -38.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Athersys's highest 3-Year average EPS without NRI Growth Rate was 78.50% per year. The lowest was -274.20% per year. And the median was 13.25% per year.


Athersys EPS (Basic) Historical Data

The historical data trend for Athersys's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys EPS (Basic) Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.18 -0.29 -10.50 -9.69 -6.07

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.15 -0.83 -0.43 -0.62 -0.15

Athersys EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Athersys's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-72.534-0)/11.945
=-6.07

Athersys's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.771-0)/24.492
=-0.15

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athersys  (OTCPK:ATHXQ) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Athersys EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Athersys's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115